TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36302195
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen therapy
Study: 32100497
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at acupoints (Tiantu, Danzhong, Zhongwan, Zusanli, Taichong, Neiguan) plus esomeprazole (20 mg, twice a day) and mosapride (5 mg, three times a day) for 14 days.
Study: 32100497
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with esomeprazole (20 mg, twice a day) and mosapride (5 mg, three times a day) for 14 days.
Study: 38985162
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 3 mg
Study: 38985162
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 7 mg
Study: 38985162
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 14 mg
Study: 35983530
Drug: Injectable salvianolic
Normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable salvianolic acid treatment
Study: 35081366
Drug: Fascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascial therapy intervention (3 weeks, 45-minute weekly sessions)
Study: 36018547
Drug: Camel milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camel milk (200 milliliters daily for 2 months)
Study: 33941940
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative oral dose of 500mg amoxicillin
Study: 33941940
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative oral dose of 400mg metronidazole
Study: 33941940
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (500mg of Amoxicillin BD, 400mg of metronidazole and painkillers postoperatively)
Study: 33981141
Drug: Rengalin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rengalin (2 tablets 2 times daily for 4 weeks)
Study: 33981141
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets 2 times daily for 4 weeks)
Study: 37950338
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg
Study: 39593191
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg
Study: 34185197
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKI)
Study: 36258248
Drug: Baclofen (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (10, 30, 60, or 90 mg)
Study: 34582477
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg/day for 10 days
Study: 34142111
Drug: CT-P17 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P17 (100 mg/ml) continued every 2 weeks (Q2W)
Study: 34142111
Drug: CT-P17 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P17 (100 mg/ml) switched from reference adalimumab
Study: 32613664
Drug: ERL monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERL monotherapy (n = 27)
Study: 36386549
Drug: Risk-based stratified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-based stratified care using Keele's STarT MSK Tool and risk-matched treatments
Study: 36386549
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (advice, education, medication, referrals)
Study: 33772710
Drug: Control (no-treatment)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (no-treatment)
Study: 33566065
Drug: Psilocybin-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin-assisted therapy
Study: 32541299
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen vaginal cream (applied for at least 5 weeks preoperatively and continued twice-weekly through 12 months postoperatively)
Study: 32716320
Drug: Pimavanserin 34
Normalized name: pimavanserin 34 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin 34 mg once daily
Study: 36342475
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg once daily
Study: 33724614
Drug: Oxygen–ozone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen–ozone therapy (O2–O3)
Study: 33569757
Drug: One implant
Normalized name: Testosterone Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: One implant in the midline of the mandibular symphysis (GA group)
Study: 33569757
Drug: Two implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two implants in the lower canine region (GB group)
Study: 33569757
Drug: Two implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two implants (GB group)
Study: 35314068
Drug: Implant Studio
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant Studio
Study: 38387597
Drug: 38% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% silver diamine fluoride (SDF) treatment
Study: 34511330
Drug: CLEC4C in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLEC4C in combination with clinical covariates from the multivariable model
Study: 36108657
Drug: Combined nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nivolumab (240 mg IV every 2 weeks) and ipilimumab (1 mg/kg IV every 6 weeks)
Study: 36108657
Drug: Combined nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nivolumab (240 mg IV every 2 weeks) and ipilimumab (1 mg/kg IV every 6 weeks) plus SBRT (24 Gy in three fractions at week 2)
Study: 38900037
Drug: Treatment-related adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related adverse events
Study: 34671996
Drug: Namodenoson 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namodenoson 12.5 mg b.d.
Study: 35526605
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg oral)
Study: 33541836
Drug: Walnut smoothie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut smoothie (48 g walnuts)
Study: 616840383
Drug: He-Mu point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: He-Mu point combination group (puncturing at ST36 and CV12)
Study: 33630475
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) chemotherapy and chemoradiation (N = 158)
Study: 33630475
Drug: HAPa immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAPa immunotherapy combined with SOC chemotherapy and chemoradiation (N = 145)
Study: 34424307
Drug: High-dose HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HBV vaccination (3 doses of 40 μg recombinant hepatitis B vaccine at 0, 1, and 2 months)
Study: 34424307
Drug: Standard-dose HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose HBV vaccination (3 doses of 20 μg each at 0, 1, and 2 months)
Study: 34424307
Drug: High-dose HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HBV vaccination
Study: 34424307
Drug: Standard-dose HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose HBV vaccination
Study: 32984946
Drug: Polaprezinc (PZ)
Normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (PZ) lozenge treatment started before chemotherapy
Study: 32984946
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (PZ lozenges initiated after onset of Grade 2 oral mucositis)
Study: 32171499
Drug: ESP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESP block with 20 mL of 0.5% ropivacaine bilaterally at T8 level
Study: 32171499
Drug: Epidural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural block with 20 mL of 0.5% ropivacaine and 1 mg of morphine at T8-T9 space
Study: 36331502
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation therapy (control group)
Study: 33028335
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three BCTs (action planning, coping planning, self-monitoring)
Study: 33028335
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of action planning and self-monitoring
Study: 34210360
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg CBDV
Study: 32485422
Drug: Active Treatment
Normalized name: Active
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Treatment A (intermittent vibrational cutaneous stimulation)
Study: 32485422
Drug: Passive Treatment
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Treatment B (no active stimulation)
Study: 32485422
Drug: Active Treatment
Normalized name: Active
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Treatment A
Study: 36149628
Drug: Combined intracervical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intracervical foley’s catheter plus intravenous oxytocin infusion
Study: 32764090
Drug: Pharmacogenomic-guided dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomic-guided dual antiplatelet therapy (DAPT) with ticagrelor for high-risk patients
Study: 35765086
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with cryotherapy (TC)
Study: 35765086
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia alone (T)
Study: 34990002
Drug: Baricitinib 2-mg
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2-mg
Study: 37634517
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment
Study: 37769311
Drug: Elagolix 150
Normalized name: elagolix 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 150 mg once daily
Study: 34451976
Drug: MVA-NP+M1 vaccine
Normalized name: Ceramide Np
DrugBank: Ceramide NP (DB14111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-NP+M1 vaccine combined with annual influenza vaccine
Study: 33688834
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug
Study: 36438071
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg every 8 hours for 4 weeks)
Study: 36438071
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same tablet shape, same dosage as silymarin)
Study: 39464932
Drug: Insulin degludec/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/insulin aspart (IDegAsp)
Study: 33773170
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Chinese medicine
Study: 35262315
Drug: Social learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social learning group (SoLG) observing positive treatment outcomes in a sham patient
Study: 32061002
Drug: Low radiation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low radiation dose contrast‐enhanced mammography (L‐CEM)
Study: 36348309
Drug: Supervised group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised group-based combined exercise therapy and education (SET)
Study: 33315489
Drug: Integral prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integral prasugrel tablets (60 mg loading dose)
Study: 33315489
Drug: Crushed prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed prasugrel tablets (60 mg loading dose)
Study: 36054089
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg daily)
Study: 32770222
Drug: Graphic warning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graphic warning labels with 'US Food and Drug Administration' sponsorship
Study: 39664835
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART)
Study: 39664835
Drug: Ultraconservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraconservative treatment (UCT)
Study: 35321886
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate infusion
Study: 33210285
Drug: Control (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (20 cc normal saline)
Study: 33121714
Drug: Baseline NT-proBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline NT-proBNP ≥125 pg/ml
Study: 36898948
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy
Study: 33412344
Drug: Nonnutritive sucking
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonnutritive sucking (NNS) twice a day for 10 days during two consecutive weeks
Study: 33412344
Drug: Combined program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined program of NNS (15 min) and swallowing exercise (SE) (15 min) daily for 10 days during two consecutive weeks
Study: 33848307
Drug: Pure essential
Normalized name: Nature's Truth Pure Essential Oil Rosemary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure essential oil therapy (sandalwood)
Study: 33848307
Drug: Blended essential
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended essential oil therapy (sandalwood-lavender)
Study: 34661770
Drug: Buccal pad
Normalized name: Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal pad of fat sandwiched with a nasolabial flap (Group I)
Study: 34661770
Drug: Buccal pad
Normalized name: Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal pad of fat combined with a collagen graft (Group II)
Study: 33065181
Drug: MRI-based IGBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-based IGBT with ureteral dose D0.1cm3 ≥77 Gy
Study: 33065181
Drug: MRI-based IGBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-based IGBT with ureteral dose D0.1cm3 <77 Gy
Study: 36856877
Drug: PGE1 treatment
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 treatment
Study: 615919275
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg RBZ
Study: 35587540
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 25 μg followed by 50 μg every 4 hours
Study: 35278780
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral grief therapy (ICBGT)
Study: 34621545
Drug: Polyethylene cover
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene cover plus Lubratex eye ointment
Study: 35231887
Drug: Dapsone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (100 mg daily)
Study: 34392146
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day anthocyanins for 12 weeks
Study: 34392146
Drug: Dose-response relationship
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response relationship of anthocyanins
Study: 36808239
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/d
Study: 33899649
Drug: MET 1000
Normalized name: Fortamet 1000mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET 1000 mg alone
Study: 33899649
Drug: FOT 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOT 24 mg and MET
Study: 33899649
Drug: FOT 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOT 24 mg alone
Study: 35158205
Drug: Durvalumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (20 mg/kg/i.v. every 4 weeks for 12 months)
Study: 33693703
Drug: Transdermal 17-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17-beta estradiol 0.1 mg/day with 30 mcg/kg/dose of rhIGF-1 administered subcutaneously twice daily (AN-IGF-1+)
Study: 33693703
Drug: Transdermal 17-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17-beta estradiol 0.1 mg/day with placebo (AN-IGF-1-)
Study: 33487271
Drug: Probiotic (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (500 mg)
Study: 39764100
Drug: Intensity-modulated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensity-modulated radiation therapy (IMRT)
Study: 34258785
Drug: k-resolution sequential
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: k-resolution sequential randomization (k-RSR) procedure
Study: 34258785
Drug: pairwise sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: pairwise sequential randomization (PSR) procedure
Study: 34006077
Drug: Photofunctionalised implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photofunctionalised implant
Study: 34006077
Drug: Untreated implant
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated implant (control group)
Study: 32156838
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline plus N‐acetylcysteine (1200mg twice a day for 2 days) (Group B)
Study: 33217362
Drug: High-dose CoronaVac
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CoronaVac (6 μg per 0.5 mL)
Study: 37379158
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (control group)
Study: 37232538
Drug: Urotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urotherapy and parasacral TENS (20 sessions, 3 times weekly, 20 min each, 10 Hz frequency, 700 μS pulse width)
Study: 34260454
Drug: 2.5 IU
Normalized name: Rabies Vaccine 2.5 IU/1 ML Injection Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 IU Botulinum Toxin (BT) injection at 1 point per side (2‐points group)
Study: 34260454
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU Botulinum Toxin (BT) injection at 2 points per side (4‐points group)
Study: 33807285
Drug: Intervention aimed
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention aimed at improving information on cardiovascular risk; details on dosage and duration not specified
Study: 33008479
Drug: Kampo medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kampo medicine (kakkonto and shosaikotokakikyosekko) administered 2.5 g of KT and 2.5 g of SSKKS three times a day for 14 days in addition to conventional treatment.
Study: 33008479
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with antipyretics, painkillers, or antitussives.
Study: 32675606
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (Xinmiao treatment system, >3 days/week, >1 h/day)
Study: 616663253
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of classroom and simulation-based courses
Study: 32651298
Drug: Oral factor
Normalized name: intrinsic factor Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral factor Xa inhibitors (combined analysis)
Study: 33385624
Drug: Standard-dose protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose protocol (120 kV, 100 mA)
Study: 33385624
Drug: Ultra-low-dose protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose protocol (80 kV, 10 mA)
Study: 33611671
Drug: Daily ultra-low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ultra-low-dose prednisolone
Study: 33045334
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg acetaminophen every 6 hours for pain, with 5 mg/325 mg oxycodone-acetaminophen for breakthrough pain
Study: 33045334
Drug: 5 mg/325
Normalized name: Xartemis XR 7.5 MG/325 MG 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/325 mg oxycodone-acetaminophen prescribed as 1 to 2 tablets every 6 hours as needed for pain (standard of care)
Study: 34144529
Drug: Withania somnifera
Normalized name: WITHANIA SOMNIFERA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withania somnifera (Ashwagandha) 6 gm in powder form or extracts in tablets, or 500-1000 mg capsule for 8-12 weeks
Study: 33878855
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of zinc and arginine (lotion A)
Study: 33878855
Drug: Placebo (lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lotion B)
Study: 37660042
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ESWT)
Study: 36167555
Drug: Anti-pseudomonal antibiotic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-pseudomonal antibiotic treatment with intravenous beta-lactam and oral ciprofloxacin for 14 days
Study: 34633418
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (continuous subcutaneous insulin infusion or multiple daily insulin injections with or without CGM)
Study: 35775453
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop (HCL) therapy
Study: 34808697
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment
Study: 38867220
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM)